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TP53 does not fully comply with the Knudson model [Knudson, A. G.,
Jr. (1971) Proc. Natl. Acad. Sci. USA 68, 820–823] in that a reduction of
constitutional expression of p53 may be sufficient for tumor predis-
position . This finding suggests a gene-dosage effect for p53 function.
To determine whether TP53 gene dosage affects the transcriptional
regulation of target genes, we performed oligonucleotide-array gene
expression analysis by using human cells with wild-type p53
(p53 /), or with one (p53 /), or both (p53 /) TP53 alleles
disrupted by homologous recombination. We identified 35 genes
whose expression is significantly correlated to the dosage of TP53.
These genes are involved in a variety of cellular processes including
signal transduction, cell adhesion, and transcription regulation. Sev-
eral of them are involved in neurogenesis and neural crest migration,
developmental processes in which p53 is known to play a role. Motif
search analysis revealed that of the genes highly expressed in p53
/ and / cells, several contain a putative p53 consensus binding
site (bs), suggesting that they could be directly regulated by p53.
Among those genes, we chose CSPG2 (which encodes versican) for
further study because it contains a bona fide p53 bs in its first intron
and its expression highly correlates with TP53 dosage. By using in
vitro and in vivo assays, we showed CSPG2 to be directly transacti-
vated by p53. In conclusion, we developed a strategy to demonstrate
that many genes are affected by TP53 gene dosage for their expres-
sion. We report several candidate genes as potential downstream
targets of p53 in nonstressed cells. Among them, CSPG2 is validated
as being directly transactivated by p53. Our method provides a useful
tool to elucidate additional mechanisms by which p53 exerts its
functions.
The tumor suppressor protein p53 is a transcription factorinvolved in important cellular processes such as cell cycle
checkpoint regulation, DNA damage response and repair, apo-
ptosis and senescence (reviewed in ref. 1). The best characterized
biochemical function of p53 is its sequence-specific transactivation
activity. A consensus binding site (bs) has been defined and
contains two copies of the 10 base pair motif RRRC(AT)(T
A)GYYY (R  A or G; Y  C or T) separated by 0–13 base pairs
(2) and is found in the regulatory regions of target genes. Recent
studies using global approaches to identify p53-regulated genes
have identified numerous putative target genes that may be directly
or indirectly regulated by p53 (3, 4). These studies have revealed
heterogeneity of the gene expression changes induced by p53
overexpression or by p53 activation after genotoxic insults, in that
the genes transcriptionally regulated by p53 vary depending on the
cell type, inducing agent, and amount of p53 in the cells.
p53 / mice develop tumors at a very early age and succumb
by 10 months of age. Heterozygous mice (p53 /) have a 50%
chance of developing tumors by 18 months of age, and almost all are
dead by 2 years of age (5). About half of the tumors that develop
in p53 / mice do not show loss of the wild-type (wt) allele (6, 7).
The wt allele is retained and encodes a functional protein able to
bind DNA and activate transcription of target genes (7). In humans,
germ-line TP53 mutations account for 70–85% of classical Li–
Fraumeni cancer predisposition syndrome (LFS) cases (8). The
LFS tumor spectrum resembles that of p53 / mice and it has
been shown that in LFS patients only 50% of tumors show loss of
heterozygosity (LOH) at the TP53 locus (9). A decrease in consti-
tutional expression of p53 should not be sufficient for tumor
formation, according to the ‘‘two-hit’’ model for tumorigenesis
proposed by Knudson (10). However, the finding that tumors
arising in p53 / individuals often retain the wt allele does not
support this model. Instead, a reduction in p53 level is sufficient to
alter the response to genotoxic stress of specific cell types in mice
(11) and might be involved in the predisposition to tumor formation
in both mice and humans.
We hypothesize that the dosage of TP53 affects its transcriptional
regulatory activity in that the amount of p53 in the cell may
determine which downstream target genes are activated, or re-
pressed, and the extent of their regulation in the absence of DNA
damage. To verify our hypothesis, we analyzed human cancer cells
with wt p53 (p53 /), or with one (p53 /) or both (p53 /)
TP53 alleles somatically knocked-out by using oligonucleotide-
based DNA microarrays. We report here that cells with different
TP53 genotypes can indeed be discriminated on the basis of global
expression levels. By using statistical analysis and computational
motif searches, we identified a subset of genes significantly corre-
lated with TP53 status. Among the genes highly expressed in
p53 / cells, but expressed lower in p53 / cells, is CSPG2,
encoding the extracellular matrix protein versican. We demonstrate
that CSPG2 is a direct target of p53. This study demonstrates the
applicability of microarray analysis to the identification of subtle
changes in gene expression, such as those associated with heterozy-
gous changes in tumor-suppressor-like genes.
Materials and Methods
Cell Lines and Treatments. The human colorectal carcinoma-derived
cell lines with a somatic knock-out of p53 (p53 /, p53 /, and
p53 /) (12) were kindly provided by B. Vogelstein (The Johns
Hopkins University, Baltimore), and cultivated in McCoy’s 5A
medium supplemented with 10% FBS (Invitrogen). The Calu6 lung
carcinoma, Saos-2 osteosarcoma, and MCF7 breast cancer cell lines
were obtained from the American Type Culture Collection
(ATCC) and maintained in DMEMhigh glucose (4.5 gliter) with
10% FBS. MCF7-E6 cells (13) were a gift of A. Fornace (National
Institutes of Health, Bethesda), and were also grown in DMEM.
Abbreviations: bs, binding site; wt, wild type; EMSA, electrophoretic mobility-shift assay.
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Growth arrest was achieved by a combination of high cell density
and serum starvation (0.25% FBS for 48 h; 0-h time point). Cells
were released from growth arrest by replating them in the presence
of serum and then harvested 12 h later for mRNA and protein
extractions (12-h time point). An aliquot of cells was fixed in ethanol
for flow cytometric analysis of DNA content. Cells were infected
with recombinant, replication-deficient adenovirus, either contain-
ing wt p53 (Ad-wtp53) or empty (Ad), kindly provided by G. Leone,
(Ohio State University). Adenoviral vectors were diluted in cell
culture medium and infections were performed in the absence of
FBS or antibiotics for 24 h at 37°C. For -irradiation, cells were
treated with 6 Gy of -rays by using a cesium-137 source. For UV
irradiation, cells were treated with 10 Jm2. Adriamycin (500
ngml) and etoposide (500 M) were added to the media for the
indicated time.
Expression Profiling. Total mRNA was extracted by using Trizol
reagent (Invitrogen) and an RNeasy kit (Qiagen, Valencia, CA).
cRNA target was prepared as reported (14) and hybridized to the
GeneChip HuGeneFL oligonucleotide arrays (Affymetrix, Santa
Clara, CA), which contain probes for 6,606 unique genes. The
cRNA samples were each hybridized to two GeneChips. Scanned
output files were visually inspected for hybridization artifacts and
scaled to an average intensity of 1,500 per gene. The expression
estimates for each gene were obtained according to the Li–Wong
‘‘full’’ model (15) and were further normalized by using simple
quadratic scaling on all genes, with the median expression for each
gene as a baseline (16). The raw data are available through the link
www.ncbi.nlm.nih.govgeo, accession no. GSE90.
TaqMan Real-Time PCR Assay. Relative expression levels and differ-
ences among p53 , p53  and p53  cells were validated
by TaqMan real-time PCR (17). The approach is detailed in
Supporting Materials and Methods, which is published as supporting
information on the PNAS web site, www.pnas.org. Briefly, the
comparative CT method was used to determine the ratio of target
and 18S rRNA endogenous control.
Statistical Analyses. All statistical comparisons were performed by
using SPLUS 6.0 for the 12 h condition alone. Each gene was
examined for concordance with the patterns in Fig. 1b. For Patterns
1 and 4, genes exhibiting Pearson correlation coefficients 0.95
were retained. For the remaining patterns, pairwise t tests were
performed comparing the expression of p53  to p53, and
p53  to p53. Genes were retained if the t test was
nominally significant at P  0.05 for the two conditions expected to
differ (according to the pattern) and P  0.05 for the two conditions
expected not to differ. As single samples of RNA were produced in
each condition, the interpretation of the P values is over repeated
arrays from the RNA sample. Although our criteria were somewhat
arbitrary and numerous multiple comparisons were performed, the
intent was to produce a manageable list of candidate genes for
further study. The choice of detection threshold relied on published
results on the relationship between average expression and stan-
dard error (16), as well as the observation that TP53 estimated
expression was near the 25th percentile in the p53  condition.
The significance of the changes in CSPG2 expression levels iden-
tified by real-time PCR was determined by using a Student’s t test
(one-tailed). Hierarchical cluster analysis was performed as out-
lined in the supporting information. Briefly, genes passing a vari-
ation filter were selected and two-way hierarchical clustering was
performed by using the programs CLUSTER and TREEVIEW (18).
Algorithm for Motif Searching. A computer algorithm was developed
to identify putative p53 bs at the genome level. A p53 consensus bs
consists of two 10-bp half-sites having the consensus sequence
5-RRRC(AT)(TA)GYYY-3, with spacing in between the two
decamers. We used a weight matrix (19) to capture the degeneracy
in the consensus sequence; each element of the matrix representing
the relative base frequency at a given position in the known bs. The
weight matrix has been derived by using a set of 56 experimentally
known p53 response elements (http://genemap.med.ohio-state.edu/
p53). By using the weight matrix, the algorithm calculates a likeli-
hood score for each half-site. The score ranges from 0 to 1, with 1
representing the optimal p53-binding site. We allowed a spacing of
0–17 bp between the two half-sites. We ran the algorithm on the
genomic regions around the first exon of each gene of interest, by
using the first exon annotations (http://genemap.med.ohio-
state.edu). Additional filters are used to capture only the highly
likely candidate p53-responsive genes. It is known that the 4
nucleotides CWWG in each palindrome most closely interact with
the p53 protein (20). Hence, we allowed at most 1 mismatch of these
8 nucleotides, and a total of 4 mismatches of the 20 nucleotides.
Plasmid Vector Construction and Luciferase Assays. The 1.26-kb
genomic fragment containing the CSPG2 promoter from nucle-
otide position 466 bp, exon 1, and the first 511 bp of intron 1
was obtained by PCR, using the following primers: forward,
GCT AGC CTC CCG AGA AGA AGT GAT CG; reverse, GCT
AGC GAA CAC CAG GCA CTG ACC AC, subcloned into the
pGL2-basic vector (Promega) and designated as CSPG2-prom.
The fragment not containing the bs was obtained by digesting
CSPG2-prom with XhoI to excise the region containing the bs
and then religating the vector (CSPG2-prombs). Double-
stranded oligonucleotides corresponding to the CSPG2 p53-
binding site (CSPG2-bs) or a mutated version of it (CSPG2-mut)
(Fig. 2a) were subcloned into the pGL2-promoter vector (Pro-
mega). The nucleotide sequence of all constructs was confirmed
by automated sequencing. Cells were plated in six-well plates
(1 	 105 per well) and transfected 24 h later with 0.5 g of
reporter construct, together with 250 ng of pCMV-wtp53 (W) or
pCMV-p53–248W (M) expression vector by using the FuGENE
6 reagent (Roche Applied Science, Indianapolis). Normalization
of transfection efficiency was obtained by cotransfection with
the pCMV--gal construct constitutively expressing the -
galactosidase gene. Cells were harvested in reporter lysis buffer
Fig. 1. Gene expression analysis of p53 ,
p53 , and p53  cells. (a) Dendrogram
showing the similarities in the expression pat-
terns of the samples (also see Fig. 4). (b) Expres-
sionpatternswithingenotypesat the12-htime
point. Schematic representation of the pat-
terns of gene expression defined by signifi-
cance testing (see Materials and Methods). A
detection threshold for gene expression esti-
mates was defined (dotted line).






























(Promega) 48 h after transfection, and luciferase activity was
quantified by using a luminometer. Representative results of
triplicate measurements of duplicate experiments with mean and
standard deviation are shown in the figures.
Electrophoretic Mobility-Shift Assay (EMSA). The double-stranded
oligonucleotides CSPG2-bs, CSPG2-mut, and the p53R2 p53 bs
(p53R2) (21) were end-labeled with polynucleotide kinase by using
[-32P]ATP. p53  cells were treated with 500 M etoposide for
48 h. Nuclear extracts were prepared by the high-salt extraction of
nuclei (22). Binding reactions with labeled oligonucleotides and
nuclear extracts were performed essentially as described (23). One
microgram of monoclonal antibody against p53, Pab421, or
Pab1801 (Santa Cruz Biotechnology), was included in the binding
reaction where indicated. The reaction mix was incubated at room
temperature for 15 min. Labeled oligomers (0.5 ng) and compet-
itors (100	) were added and incubated at 30°C for 15 min.
DNA-protein complexes were resolved on 4% polyacrylamide gels
in 0.5X TBE buffer. The gels were dried and autoradiographed.
Western Blotting. Cell lysates were prepared as reported (24) and 40
g of total protein was resolved by SDSPAGE (4–12% gradient
gels, Bio-Rad). Primary antibodies (DO-1 for p53, F-5 for p21WAF1,
and D-10 for -tubulin) were from Santa Cruz Biotechnology.
Equal loading of proteins was monitored by hybridizing the same
membrane with -tubulin antibody.
Results and Discussion
Global Expression Profiling of Isogenic Cell Lines with Different TP53
Status. The HCT116 colorectal cancer cell line containing wt p53
was previously used for targeted homologous recombination of the
TP53 alleles (12). p53 , p53 , and p53  cells were
growth-arrested (0-h), then released (12-h), and their mRNA was
studied by means of global gene expression. Duplicate hybridiza-
tions of a single cRNA sample from each condition resulted in the
mean correlation of gene expression of r  0.983 across all genes,
compared with r  0.856 for nonduplicate arrays. Validation of
microarray gene expression results was carried out by TaqMan
real-time PCR for seven genes (see Fig. 3, which is published as
supporting information on the PNAS web site). When we per-
formed hierarchical clustering using 5,000 genes that passed our
filtering criteria, the three cell lines clustered in separate branches
in the dendrogram that summarizes the similarities in gene
expression patterns among samples (Fig. 1a and Fig. 4, which is
published as supporting information on the PNAS web site). This
result supports the hypothesis that cells differing in the number
of functional TP53 alleles can be distinguished, based on gene
expression.
Effect of TP53 Gene Dosage on Gene Expression. To select the genes
of greatest interest, we defined six expression patterns for genes that
are differentially expressed among the cell lines (Fig. 1b). The
patterns correspond to what might be described as codominant,
dominant, and recessive effects of wt TP53 alleles on gene expres-
sion. It is notable that TP53 itself showed the highest correlation
coefficient with TP53 status of any gene on the array (pattern 1 in
Fig. 1b). We further validated TP53 expression profiles by using
real-time PCR (Fig. 3), and the correlation between TaqMan and
GeneChip expression estimates for TP53 was 0.9. For each pattern,
lists of genes were produced in significance testing as described in
the Materials and Methods. To increase our chances of discovering
new p53 targets, we further restricted our study to genes that had
essentially undetectable expression in one or more of the p53
conditions as presumed by the genetic model (illustrated in Fig. 1b).
We used a detection threshold of the 25th percentile for all
expression estimates, based on previous results (16). The combi-
nation of significance testing and detection threshold for the 12-h
time point resulted in a list of 35 genes of interest (Table 1),
representing only 0.5% of the genes on the array. With such an
abbreviated list it is feasible to perform careful computational
identification of p53 bs, as described below. It is evident from Table
1, that in nonstressed cells, TP53 gene dosage affects the transcrip-
tion of a plethora of genes involved in many cellular functions
Fig. 2. CSPG2 contains a functional p53 bs. (a) Schematic representation of the
reporter gene constructs used. The two decamers that constitute the identified
p53 bs in CSPG2 intron 1 are underlined. SV, minimal promoter. (b) Activation of
the CSPG2-prom construct by wt, but not mutant, p53. pGL2-P, CSPG2-prom, or
CSPG2-prombswerecotransfected,alongwithaconstructencodingwtp53(W),
mutant p53–248W (M), or pCMV empty expression vector (C) in Saos-2 cells. (c)
Saos-2 cells were cotransfected with CSPG2-bs, CSPG2-mut, or pGL2-P empty
vector, and W, M, or C. wt, but not mutant, p53 activates transcription of a
heterologous promoter in the presence of the CSPG2 p53 bs. Mutations in the
CSPG2 p53 bs abolish this activation. (d and e) MCF7 and MCF7-E6 cells were
transfected with the constructs in a. When CSPG2-prom was transfected into
MCF7-E6 cells (p53 null), no increase in the luciferase activity was observed. In
contrast, transfection of this construct into MCF7 cells showed a marked increase
in luciferase activity. Similar results were observed when transfecting CSPG2-bs.
For b–e, luciferase activity is shown as relative light units (RLU), and for Saos2 cells
it is shown as fold induction relative to the activity of the reporter vector in the
absence of p53. (f) EMSA was done by using radiolabeled CSPG2-bs, CSPG2-mut,
and p53R2 oligonucleotides with nuclear extracts from p53  cells treated
with 500 M etoposide.




















including signal transduction, cell adhesion, and transcription reg-
ulation. The majority of the published transcriptional targets of p53,
except p21WAF1 and MDM2 (see Table 1), did not show a high
correlation with TP53 status and were not significantly differentially
expressed among the three cell lines. These genes were identified as
p53-responsive genes on ectopic overexpression of p53 or on
treatment with DNA damaging agents. Our experimental system
compares the constitutional levels of gene expression in cells that
differ for the number of wt TP53 alleles without external pertur-
bation, and therefore the results we obtained are not entirely
surprising.
Functional Analysis of the Genes Affected by the Dosage of TP53. As
shown in Table 1, most of the genes we identified as being
differentially expressed among the three cell lines belong to
expression pattern 3 (21 genes). This finding suggests that
whether there are one or two functional TP53 alleles makes a
difference in the ability to regulate gene expression, perhaps
because p53 needs to reach a threshold to properly regulate some
of its transcriptional targets. Note that 11 of 21 genes in pattern
3 belong to the cluster of genes highly expressed in p53  cells
when hierarchical clustering is performed (Fig. 4a). Of the genes
in pattern 3, it is interesting to highlight SIAH1. This gene is the
human homologue of the Drosophila seven in absentia (Sina)
gene and is a putative tumor suppressor gene (25). SIAH1 is
up-regulated during the first few hours of apoptosis induced by
wt p53 (26), thereby supporting our finding that SIAH1 tran-
scriptional regulation may depend on the amount of p53. Several
Table 1. List of 35 genes selected using the criteria illustrated in Fig. 1b
Probe set ID Gene symbol Gene ontology bio process, cell component, molecular function* Correlation† P value‡
Pattern 1 (6 genes)
M22898at TP53 Apoptosis, cell cycle checkpoint, DNA repair, transcription factor, tumor suppressor 0.9858 0.0003
K02766at C9 Complement component, hemolysin 0.9315 0.0069
U44429at TPD52L1 Oncogenesis 0.9113 0.0114
M16987at F5 Blood coagulation 0.8894 0.0177
M64358at RHOM3A Unknown function 0.888 0.0181
M26061at PDE6A Vision, cGMP-specific phosphodiesterase 0.8653 0.026
Pattern 2 (1 gene)
X82539at MAGEB1 Tumor antigen 0.0416
Pattern 3 (21 genes)
U16306at CSPG2 Cell adhesion, developmental processes, cell recognition 0.0002
M96843at ID2B Dominant-negative helix–loop–helix transcription factor, DNA binding, protein binding,
developmental processes
0.0041
L25798at HMGCS1 Lipid metabolism 0.0085
X57025at IGF1 Signal transduction, positive control of cell proliferation, cell motility 0.0135
D82345at TMSNB Unknown function 0.0164
U12535at EPS8 Signal transduction, cell proliferation, EGF receptor signaling pathway, SH3SH2 adaptor
protein
0.0169
Z25521sat CD47 Signal transduction 0.0199
L22075at GNA13 Signal transduction, cell motility, heterotrimeric G-protein GTPase,  subunit 0.0237
U18242at CAMLG Signal transduction, defense response 0.0243
L19871at ATF3 Cell-matrix adhesion, integrin-mediated signaling pathway, oncogenesis, transcription
corepressor
0.0305
S41458at PDE6B Phototransduction, visible light, vision, cGMP-specific phosphodiesterase 0.0316
M86852at PXMP3 Protein-peroxisome, targeting peroxisome, organization, and biogenesis 0.034
Y11897at CHIC1 Unknown function 0.0359
U44772at PPT1 Neurogenesis 0.036
U63295at SIAH1 Axon guidance, embryogenesis and morphogenesis, apoptosis, neurogenesis 0.0378
X05997at LIPF Hydrolase, lipid degradation, glycoprotein 0.0387
X66087at MYBL1 Transcription regulation from Pol II promoter, transcription-activating factor 0.04
Y08991at PIK3R4 Nonselective vesicle transport enzyme activator 0.0409
Z46788at CYLC2 Cell shape, cell size control, cytoskeletal structural protein 0.0434
Z15108at PIKCZ Antiapoptosis, signal transduction, protein phosphorylation, protein kinase 0.0436
D87127at TLOC1 Cotranslational membrane targeting 0.0483
Pattern 4 (3 genes)
AB000220at SEMA3C Axon guidance, cell growth and maintenance, immune response, drug resistance 0.9711 0.0012
M60047at HBP17 Signal transduction, negative control of cell proliferation, cell–cell signaling, heparin binding 0.8764 0.022
X02874at OAS1 Nucleobase, nucleoside, nucleotide, and nucleic acid metabolism 0.8326 0.0397
Pattern 5 (2 genes)
D38491at KIAA0117 RNA-binding protein 0.0019
U11313at SCP2 Acyl-CoA metabolism, peroxisome organization and biogenesis, sterol carrier protein
X-related thiolase
0.0085
Pattern 6 (2 genes)
U67988at DLGAP1 Synaptic transmission protein binding 0.0089
U79289at LOC148357 Unknown function 0.0094
Known targets
U33202sat MDM2 Negative control of cell proliferation oncogenesis 0.8824 0.0199
U33203sat MDM2 Negative control of cell proliferation oncogenesis 0.8821 0.02
U09579at CDKN1A Induction of apoptosis, cell cycle arrest, negative control of cell proliferation, regulation of
CDK activity
0.8785 0.0213
*Gene annotation based on the GeneOntology Consortium (www.geneontology.org) and Affymetrix (www.affymetrix.comanalysisindex.affx).
†Pearson’s correlation coefficient for correlation with p53 status.
‡Genes with P values 0.05 were considered. Known p53 target genes that show a high correlation with p53 status but did not meet the threshold criteria are
reported at the bottom.






























of the genes listed in Table 1 play a role in neurogenesis or neural
crest migration, or are highly expressed in the nervous system,
such as PPT1, CSPG2, Id2, SEMA3C, IGF1, and CHIC1.
In p53-deficient embryos, a subset presents with a spectrum of
developmental defects, including failure in neural tube closure,
which leads to exencephaly and embryonic death, and cranio-
facial abnormalities (27, 28). This result suggests that p53 may
play a role in neurogenesis, but there is functional redundancy
and other genes can compensate for its absence. Transgenic
mouse models having a reporter gene under the control of a
p53-regulated promoter, such as the mdm2 promoter, have
identified high transcriptional activity of p53 in the brain and
haploinsufficiency in the level of p53-mediated response to
-irradiation of heterozygous embryos (29). These and our data
support the hypothesis that the dose of TP53 affects the tran-
scriptional regulation of downstream genes. Some of these genes
require two intact TP53 alleles, or two mutant alleles, for their
expression in nonstressed cells.
Identification of Genes Directly Regulated by p53. Our experimental
approach allowed us to identify genes whose transcriptional regu-
lation is affected by TP53 gene dosage. Of those genes, some might
be directly regulated by p53 through binding to a p53 bs. We
selected the genes whose expression level was increased in the
presence of p53 (patterns 1–3) and analyzed 10 kb of the genomic
sequence around the first exon of each of these genes (3 kb
upstream and about 7 kb downstream to exon 1) for the presence
of a consensus p53 bs by using a similarity matrix. For each putative
p53 bs we obtained a score as a measure of its similarity to the
published consensus bs: the higher the score for a particular
sequence, the closer to the published consensus (optimal consensus
score  1). No more than four mismatches to the canonical binding
site were allowed. The efficiency of the computational analysis was
evaluated by using previously identified functional p53 bs. The p53
bs of MDM2, p21WAF1, IGFBP3, and GADD45 were recognized by
the algorithm (data not shown). Of the 27 genes analyzed (excluding
TP53), we found 10 that contained promising putative p53-binding
sites (Table 3, which is published as supporting information on the
PNAS web site). The genes with the highest summed score (and
fewer mismatches) were CSPG2 and GNA13. The CSPG2 putative
p53 response element is located in the 5 portion of the first intron,
424 bp from the end of the untranslated exon 1. MDM2 and
IGFBP3, two known p53 target genes, also possess a functional p53
bs in intron 1 (30, 31) The putative p53 bs of GNA13 is about 2.2
kb upstream of the transcriptional start site, similar to the position
of the p53 response element in the p21WAF1 gene promoter (32).
CSPG2 was the most highly significant gene in pattern 3, and
showed the second-highest similarity score in Table 3. This gene
thus emerged as the clearest candidate gene to validate experimen-
tally. We performed TaqMan real-time PCR using the same
mRNA that had been used for the microarray analysis to confirm
the TP53 dose-dependent regulation of CSPG2 expression. The
results agreed well with the microarray data (Fig. 3). The use of the
heterozygous cells, in addition to p53  and p53  cells,
allowed us to identify the TP53 dose-dependent regulation of
CSPG2 expression.
p53 Activates the Transcription of the CSPG2 Gene in Reporter Gene
Assays. To verify that the identified CSPG2 p53 bs is functional, we
performed reporter gene assays. The CSPG2 promoter has been
characterized and the region from 466 to 244 relative to the
transcription start site in exon 1 shows maximal promoter activity
in reporter gene assays (33). We cloned a 1.26-kb fragment,
comprising the genomic region from 466 to the putative CSPG2
p53 bs in intron 1, upstream to a promoterless luciferase reporter
gene (pGL2-basic vector) to obtain the construct designated
CSPG2-prom (Fig. 2a). A similar construct without the p53 bs was
also made (CSPG2-prombs) (not shown). Luciferase assays
showed that the CSPG2-prom construct was activated more than
200-fold by cotransfection with wt p53 (Wp53) in Saos-2 p53-null
cells compared with the control plasmid (pGL2-P) (Fig. 2b).
Mutant p53 did not activate CSPG2-prom. The CSPG2-prombs
construct was not activated by wt p53, indicating that the identified
CSPG2 p53 bs is required for the p53-dependent activation of the
reporter gene. To confirm that the identified putative p53 bs
mediates the p53-induced transactivation of CSPG2, a copy of the
21-bp CSPG2 response element (CSPG2-bs) or a mutated oligo-
nucleotide (CSPG2-mut) was cloned upstream to a luciferase gene,
preceded by the minimal promoter element of the pGL2-promoter
vector (Fig. 2a). Cotransfection of the CSPG2-bs construct and the
wt p53 expression vector in Saos2 cells increased promoter activity
by more than 15-fold (Fig. 2c). Mutation of the putative CSPG2
p53-binding site (CSPG2-mut) abolished transactivation by p53. No
activation was observed on cotransfection of the mutant p53
construct.
We also cotransfected the constructs in Fig. 2a into MCF7 cells,
harboring wt p53, and into MCF7-E6 cells constitutively expressing
the E6 protein from human papilloma virus (HPV) type 16, and
therefore p53-null. Transfection of CSPG2-prom in MCF7 cells
gives high luciferase activity compared with the pGL2-P empty
vector, because of the endogenous wt p53 (Fig. 2d). MCF7-E6 cells
fail to activate the CSPG2-prom construct. Transfection of CSPG2-
prombs gives a level of luciferase activity comparable to pGL2-P
in both cell lines. Luciferase activity is dramatically increased on the
transfection of CSPG2-bs into MCF7, but not in MCF7-E6 cells
compared with vector control (Fig. 2e). In conclusion, the CSPG2
p53 bs is a functional p53 response element.
p53 Protein Binds to the CSPG2 Intron 1 Response Element in Vitro. To
directly show the interaction of p53 protein and the CSPG2 p53 bs,
an EMSA was performed. The 21-bp p53-binding site in CSPG2-bs
was used as a probe (Fig. 2a) and nuclear extracts from p53 
cells treated with etoposide (which increases the level of p53
protein) were used in the binding reaction. We used CSPG2-mut as
a negative control probe and an oligonucleotide corresponding to
the p53 bs in the p53R2 gene (p53R2) (21) as a positive control. The
mobility of the labeled CSPG2-bs probe was shifted in the presence
of nuclear extracts containing activated p53 (Fig. 2f, lane 6) and
formed a binding complex with p53 itself. The binding complex was
diminished by increasing amounts of self-competitor (lane 12) as
well as by consensus p53 bs (lane 11), but not by the nonspecific
competitor CSPG2-mut (lane 13). No shifted bands were observed
when the CSPG2-mut oligonucleotide probe was used. Supershift
of the band observed in the presence of the CSPG2-bs oligonucle-
otide when anti-p53 monoclonal antibodies Pab421 and Pab1801
were used demonstrates that p53 specifically binds the CSPG2-bs
sequence.
Induction of Endogenous CSPG2 Gene Expression by p53. To deter-
mine whether the endogenous level of CSPG2 is affected by p53, we
infected p53-null Calu6 cells with adenoviral constructs. While on
infection of the empty vector (Ad) we observed no activation of
CSPG2 expression, on infection of a vector overexpressing wt p53
(Ad-p53) we observed a substantial increase of endogenous CSPG2
expression (Fig. 5, which is published as supporting information on
the PNAS web site). These experiments demonstrate a p53-
dependent induction of CSPG2 in Calu6 cells. Infected cells express
p53 at levels likely to be higher than those encountered in vivo. To
assess CSPG2 transcriptional activation at more physiologic levels
of p53, we treated cells with DNA-damaging agents known to
stabilize p53. We treated p53 , p53 , and p53  cells
with radiation (UV and ) and with the drugs Adriamycin and
etoposide. The results obtained by TaqMan real-time PCR show
that CSPG2 expression is induced in a p53-dependent fashion on
treatment with -rays or Adriamycin (Table 2). No induction of
CSPG2 expression was observed after UV or etoposide treatment




















(data not shown). To verify that in our experimental conditions p53
was stabilized and also active in its transactivation ability, we
assessed the induction of p21WAF1 in the same samples by Western
blotting. In all of the conditions used, p53 was able to transactivate
p21WAF1 (data not shown). Therefore, we conclude that CSPG2
expression is induced in a p53-dependent manner after specific
genotoxic stress.
Conclusions
Gene expression array analysis allowed us to compile a list of genes
regulated by TP53 gene dosage in the absence of cellular stress.
Among them, we found genes involved in a variety of cellular
processes. In particular, we noted the transcriptional regulation of
genes encoding proteins highly expressed in the nervous system,
involved in neural crest cell migration and neural tube closure. p53
plays a role in neurogenesis, as indicated by the fact that a subset
of p53-deficient mice show defects in neural tube closure and other
abnormalities (27, 28). p53 is not required to promote the normal
developmental program, but may be involved in fine tuning the
transcriptional regulation of genes required for neural crest cell
migration, developmentally regulated apoptosis, or other cellular
mechanisms. It is therefore possible that some of the genes listed
in Table 1 mediate important developmentally related functions
of p53.
Recently, it has been shown that a decrease in the constitutional
expression level of the APC gene predisposes to familial adenoma-
tous polyposis (34), demonstrating that small quantitative changes
in gene expression are involved in complex human diseases. A
reduced level of p53 predisposes to tumor formation in mice (6, 7)
and possibly in humans. The fact that the transcriptional regulation
of a subset of genes, including CSPG2, SIAH1, and others, seems
to require a double dosage of wt TP53 suggests that these down-
stream targets could be involved in tumor predisposition.
By using a motif identification approach, we identified potential
direct targets of p53. We demonstrated that CSPG2, a gene highly
expressed in p53  but expressed lower in p53  cells, is a
direct target of p53. CSPG2versican is an anti-cell adhesive
molecule that negatively regulates neural crest cell migration and
axon outgrowth (35). High expression of CSPG2 has been found in
the peritumoral stromal tissue of early stage prostate cancers, and
of breast cancers, and it is associated with an aggressive tumor
behavior (36, 37). Also, CSPG2 is silenced in colorectal cancer
because of promoter hypermethylation (38, 39), suggesting that,
depending on the tissue, this protein may either inhibit or stimulate
cell motility and local invasion. In colorectal cancer, CSPG2
methylation is an early event possibly involved in the predisposition
to tumorigenesis or its progression (39). Our finding that the dosage
of TP53 affects CSPG2 expression supports the hypothesis of such
a role for this gene.
Our analysis of nonstressed cells highlights additional regulatory
pathways that may be of importance to the understanding of p53
function in the normal cycle of cells. Furthermore, the knock-out
design offers an opportunity to assess the requirement for one or
two (haploinsufficiency) functional alleles of TP53 to mediate the
transcriptional regulation of specific genes. The fascinating possi-
bility that some of the genes we identified might be involved in the
predisposition to tumor formation warrants further studies.
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Table 2. Relative expression level of CSPG2
Sample Relative expression level* P †
p53  untreated 1.00 
 0.043
p53  adriamycin 24 h 4.315 
 0.501 0.0002
p53  untreated 1.766 
 0.262
p53  adriamycin 24 h 2.326 
 0.418 0.0602
p53  untreated 1.181 
 0.138
p53  adriamycin 24 h 1.129 
 0.154 0.3452
p53  untreated 1.05 
 0.367
p53  6 Gy 6 h 1.059 
 0.258 0.4873
p53  6 Gy 12 h 2.313 
 0.142 0.0026
p53  6 Gy 24 h 5.044 
 0.586 0.0003
Cells were treated with 500 ngml adriamycin or -irradiation (6 Gy) and
mRNA was isolated at the indicated times after treatment.
*Values represent the means of two independent experiments in triplicate 

standard deviation, which were standardized by using the 18S rRNA internal
control.
†P values were calculated by Student’s t test comparing treated and untreated
samples.
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